Experts Highlight Funding, New Therapies and Access Gaps in Cancer Fight
Leading cancer researchers at a New York health forum stressed recent breakthroughs like mRNA vaccines and immunotherapy, while warning that equitable access remains essential.
During the TIME100 Health Leadership Forum in New York, top cancer experts examined the progress made against the disease and the work still required. Shane Jacobson, chief executive of the American Cancer Society and its Cancer Action Network, attributed recent gains to sustained philanthropic and federal investment, citing the rapid pace of innovations such as the mRNA cancer vaccine announced by Moderna and Merck. Andrea Cercek of Memorial Sloan Kettering Cancer Center described how vaccines and immunotherapy harness the immune system, noting her team's study in which patients with a specific rectal cancer showed no detectable tumors after six months of treatment, eliminating the need for surgery or radiation.
Both speakers emphasized that the true impact of these advances depends on universal access to new drugs and therapies. The discussion ended with a consensus that a cure will likely involve multiple approaches, with early detection and prevention playing a central role. Sponsors of the forum included the American Cancer Society, Kite (a Gilead Sciences company), Insulet, Musely and the NMDP.
Why it matters
Understanding breakthroughs and access challenges helps gauge how close we are to turning cancer into a manageable, possibly curable, condition.
In this story
